Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Will RWD Get Real In Japan? Govt Moves To Build Digital Health Records

Pharma Benefits Down Road?

Executive Summary

To enable broader use of clinical data in its digital health care system, Japan has kickstarted digitization measures to link all patient records to an online individual ID system. While the government aims to allow real-world data and evidence for the pharmaceutical sector in the long run, Scrip explores the reality of current projects and measures in the country.

You may also be interested in...



Japan’s All-Genome Project Hopes To Push Pharma R&D

Japan is aiming for the betterment of pharma R&D and medical services for rare disease patients by building a database connecting genome analysis data and clinical records. While several clinical studies are planned for the next couple of years, there are also concerns around the actual trickle-down of benefits to patients and data privacy.

Integrating Data: Daiichi, Takeda Join Lifestyle Project To Inform R&D

The data collected from wearable devices for a year will provide lifecycle data to a much long-termed study with various health data. The study will not only contribute to drug discovery and personalized healthcare by the firms in near future, but also suggests bigger goals by Japan’s healthcare industry.

Japan Pushing Forward In Global Scrum For Cancer Leads

Japan is forging ahead with a national project to elucidate cancer-related gene alterations in its population, both to identify responder patients for possible inclusion in clinical trials for targeted therapies and to inform the development of new treatments.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC147321

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel